Celebrating women in life sciences and healthcare: insights and challenges from Hannah Kuchler
Law firm Stephenson Harwood LLP recently held an event for women in life sciences and healthcare, to celebrate International Women's Day and the achievements of women working in the sector. The evening included a fireside chat with the Emmy-nominated, Loeb-winning Hannah Kuchler, Global Pharmaceutical Editor for the Financial Times, and Alexandra Pygall, head of life sciences and healthcare at Stephenson Harwood.
Some of the key themes from the discussion included:
- Diversity and Inclusion in Science and Business: The importance of diverse backgrounds was discussed, both in understanding complex scientific topics and in leadership. Hannah gave the example of influential women like Jennifer Doudna and Özlem Taraki to highlight the value of female leadership in science and business but acknowledges that challenges remain, such as low investment in women's health, with only 2% of government funding going on pregnancy, fertility, and birth, and the difficulty women face in raising capital in a male-dominated investor landscape.
- Emerging Scientific and Technological Developments: Hannah flagged that it is an exciting time in the industry with a raft of advancements like blood-brain transporters reflecting ongoing innovation in the scientific community. Hannah predicts obesity, Robert F Kennedy's appointment, China, and AI all featuring as key themes in the sector over the next few months.
- Economic and Political Influences on the Industry: The discussion touched on how geopolitical actions, such as US initiatives and executive orders, might affect global dynamics, particularly in the pharmaceutical industry. Concerns relating to the effect on European pharma, especially vaccine makers, highlight the potential impact of US investor influence and political risks on international business strategies.
- Investment Challenges and Opportunities: Hannah noted that the industry faces significant financial challenges, particularly in the UK, where despite plenty of talent a lack of follow-on capital hinders growth. Post-COVID investment caution in biotech startups and the strategic PR approaches of obesity companies illustrate the complex landscape of funding and public perception in the life sciences sector.
